Updated: January 19, 2026

Xeljanz XR Access Issues: What Providers and Prescribers Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Is There a Clinical Drug Shortage of Xeljanz XR?
Prior Authorization Landscape in 2026
Step Therapy Requirements: What to Document
Boxed Warnings and Monitoring Requirements
Recommended Monitoring Schedule
Helping Patients Bridge Access Gaps
Key Dosing Reminders

A clinical reference for providers on Xeljanz XR prior authorization, step therapy requirements, safety monitoring, and helping patients navigate access barriers in 2026.

Xeljanz XR (tofacitinib extended-release), Pfizer's once-daily oral JAK inhibitor, is approved for five indications: rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), ulcerative colitis (UC), and polyarticular course juvenile idiopathic arthritis (pcJIA; tablets only). Despite consistent manufacturing supply, many patients face significant delays filling their prescriptions. This guide covers what prescribers need to know to support patients navigating these barriers in 2026.

Is There a Clinical Drug Shortage of Xeljanz XR?

No. Xeljanz XR is not on the FDA's official shortage list as of 2026. Pfizer has maintained consistent supply of tofacitinib extended-release tablets. The access challenges your patients are experiencing are driven by payer policies, not manufacturing constraints.

Prior Authorization Landscape in 2026

Prior authorization (PA) is required for Xeljanz XR by virtually all commercial payers and Medicare Part D plans. PA criteria typically include:

Confirmed diagnosis with appropriate ICD-10 coding (RA: M05/M06; PsA: L40.5/M07; AS: M45; UC: K51)

For RA: inadequate response or intolerance to methotrexate; for PsA/AS/UC: inadequate response or intolerance to one or more TNF blockers

Documentation of prior treatments (DMARDs, biologics, durations, reason for discontinuation)

Prescriber specialty noted (rheumatologist for RA/PsA/AS; gastroenterologist for UC in some plans)

Baseline lab values (CBC, LFTs, lipids) confirming patient meets safety criteria to initiate

Pfizer's XELSOURCE team (1-844-935-5269) can assist your office with PA submissions, appeals, and peer-to-peer requests. Consider proactively enrolling patients in XELSOURCE at the time of prescribing to minimize delays.

Step Therapy Requirements: What to Document

Most payers require step therapy for Xeljanz XR, meaning patients must have an adequate trial and documented failure of less expensive treatments. For RA, this typically means methotrexate or another conventional DMARD, followed by at least one TNF blocker. For UC, it often means failure of a TNF blocker (e.g., infliximab or adalimumab).

Well-documented records are critical. Specify the drug name, dose, duration, and reason for failure (inadequate response, adverse effect, intolerance). Vague documentation such as "patient tried biologics" is frequently rejected by payer reviewers. Include objective measures where possible (DAS28, CDAI, Mayo score for UC).

Boxed Warnings and Monitoring Requirements

Xeljanz XR carries an FDA Boxed Warning covering four areas: serious infections, all-cause mortality, malignancy, and thrombosis. These were updated in September 2021 following post-marketing safety data from the ORAL Surveillance study. Key prescribing implications:

Infections: Screen for latent TB before initiating; test for hepatitis B and C. Interrupt therapy if serious infection develops. Avoid in patients with active infections.

Mortality/CV risk: Higher all-cause mortality was observed with tofacitinib vs. TNF blockers in RA patients ≥50 with at least one CV risk factor. Use TNF blockers first in this population when possible.

Malignancy: Higher rates of lymphoma and lung cancer vs. TNF blockers in RA patients. Caution in current or former smokers and patients with known malignancy.

Thrombosis: Increased risk of pulmonary embolism, DVT, and arterial thrombosis. Avoid 22 mg/day dose for RA, PsA, and AS.

Recommended Monitoring Schedule

Per FDA labeling, monitor the following at initiation and during treatment:

CBC (ANC, hemoglobin, lymphocytes) at baseline, 4–8 weeks after initiation, then every 3 months

Lipid panel at baseline and 4–8 weeks after initiation (tofacitinib increases LDL and HDL)

Liver function tests at baseline and periodically

Latent TB testing (IGRA or TST) before starting; monitor during therapy

Helping Patients Bridge Access Gaps

When a patient faces a PA delay or insurance gap, several options can help:

Free 30-day trial voucher: Pfizer offers a one-time bridge supply for new patients through XELSOURCE

Pfizer Co-Pay Savings Program: Commercially insured patients can pay as little as $0/month (up to $15,000/year)

Pfizer RxPathways: Uninsured/underinsured patients may receive medication at no cost (income-based)

If your patient needs help finding which pharmacies can dispense it, refer them to medfinder for providers — a service that contacts pharmacies on behalf of patients to locate available stock.

Key Dosing Reminders

RA, PsA, AS: Xeljanz XR 11 mg once daily. The 22 mg/day dose is NOT recommended for these indications.

UC induction: Xeljanz XR 22 mg once daily for up to 8 weeks; discontinue if no response by week 16. Maintenance: 11 mg once daily (or 22 mg if needed for UC).

Renal/hepatic impairment: Reduce to 5 mg once daily for moderate renal or hepatic impairment. Avoid in severe hepatic impairment.

CYP3A4 inhibitors: Reduce dose with strong CYP3A4 inhibitors (e.g., ketoconazole). Avoid strong CYP3A4 inducers (e.g., rifampin).

For a practical guide on helping your patients locate and access Xeljanz XR, see our provider guide to finding Xeljanz XR for patients.

Frequently Asked Questions

Common ICD-10 codes for Xeljanz XR PA include: M05/M06 (RA), L40.5/M07.3 (PsA), M45 (AS), K51 (UC). Include the most specific code available and attach relevant clinical documentation including disease activity scores and prior treatment history.

Yes. Most payers have a step therapy exception process for medical necessity. Document specifically why TNF blockers are contraindicated (e.g., history of demyelinating disease, prior malignancy, specific adverse reaction). A peer-to-peer call with the plan's medical director can often resolve this quickly.

Per FDA labeling, obtain: CBC (ANC must be ≥1,000 cells/mm³, lymphocytes ≥500 cells/mm³, hemoglobin ≥9 g/dL), LFTs, lipid panel, and latent TB testing (IGRA or TST). Also screen for hepatitis B and C. Document these baseline values for PA submissions.

Contact XELSOURCE (1-844-935-5269) to request a bridge supply for new patients or to expedite the PA. For existing patients, consider an urgent peer-to-peer appeal. If the delay will be prolonged, consult with the patient about bridging with oral corticosteroids or a similar agent per clinical judgment.

The 22 mg dose is only appropriate for UC induction (first 8 weeks of therapy). It is NOT recommended for RA, PsA, or AS due to increased risks of mortality, malignancy, and thrombosis observed in post-marketing safety studies. Use 11 mg once daily for all non-UC induction indications.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards